Literature DB >> 22020083

Fall in hematocrit per 1000 parasites cleared from peripheral blood: a simple method for estimating drug-related fall in hematocrit after treatment of malaria infections.

Grace Olusola Gbotosho1, Titilope Okuboyejo, Christian Tientcha Happi, Akintunde Sowunmi.   

Abstract

A simple method to estimate antimalarial drug-related fall in hematocrit (FIH) after treatment of Plasmodium falciparum infections in the field is described. The method involves numeric estimation of the relative difference in hematocrit at baseline (pretreatment) and the first 1 or 2 days after treatment begun as numerator and the corresponding relative difference in parasitemia as the denominator, and expressing it per 1000 parasites cleared from peripheral blood. Using the method showed that FIH/1000 parasites cleared from peripheral blood (cpb) at 24 or 48 hours were similar in artemether-lumefantrine and artesunate-amodiaquine-treated children (0.09; 95% confidence interval, 0.052-0.138 vs 0.10; 95% confidence interval, 0.069-0.139%; P = 0.75) FIH/1000 parasites cpb in patients with higher parasitemias were significantly (P < 0.0001) and five- to 10-fold lower than in patients with lower parasitemias suggesting conservation of hematocrit or red cells in patients with higher parasitemias treated with artesunate-amodiaquine or artemether-lumefantrine. FIH/1000 parasites cpb were similar in anemic and nonanemic children. Estimation of FIH/1000 parasites cpb is simple, allows estimation of relatively conserved hematocrit during treatment, and can be used in both observational studies and clinical trials involving antimalarial drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 22020083     DOI: 10.1097/MJT.0b013e31822119d9

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  5 in total

1.  Therapeutic efficacy and effects of artemisinin-based combination treatments on uncomplicated Plasmodium falciparum malaria -associated anaemia in Nigerian children during seven years of adoption as first-line treatments.

Authors:  Akintunde Sowunmi; Kazeem Akano; Godwin Ntadom; Adejumoke I Ayede; Folasade O Ibironke; Temitope Aderoyeje; Elsie O Adewoye; Bayo Fatunmbi; Stephen Oguche; Henrietta U Okafor; Ismaila Watila; Martin Meremikwu; Philip Agomo; William Ogala; Chimere Agomo; Onikepe A Folarin; Grace O Gbotosho; Christian T Happi
Journal:  Infect Dis Poverty       Date:  2017-02-07       Impact factor: 4.520

2.  Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children.

Authors:  Stephen Oguche; Henrietta U Okafor; Ismaila Watila; Martin Meremikwu; Philip Agomo; William Ogala; Chimere Agomo; Godwin Ntadom; Olajide Banjo; Titilope Okuboyejo; Gboye Ogunrinde; Friday Odey; Olugbemiga Aina; Tolulope Sofola; Akintunde Sowunmi
Journal:  Am J Trop Med Hyg       Date:  2014-09-22       Impact factor: 2.345

3.  Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria.

Authors:  Akintunde Sowunmi; Kazeem Akano; Adejumoke I Ayede; Godwin Ntadom; Temitope Aderoyeje; Elsie O Adewoye; Bayo Fatunmbi
Journal:  BMC Infect Dis       Date:  2016-06-01       Impact factor: 3.090

4.  Temporal changes in haematocrit following artemisinin-based combination treatments of uncomplicated falciparum malaria in children.

Authors:  Akintunde Sowunmi; Kazeem Akano; Adejumoke I Ayede; Godwin Ntadom; Bayo Fatunmbi; Temitope Aderoyeje; Elsie O Adewoye
Journal:  BMC Infect Dis       Date:  2015-10-26       Impact factor: 3.090

5.  Early rising asexual parasitaemia in Nigerian children following a first dose of artemisinin-based combination treatments of falciparum malaria.

Authors:  Akintunde Sowunmi; Kazeem Akano; Adejumoke I Ayede; Elsie O Adewoye; Godwin Ntadom; Bayo Fatunmbi; Grace O Gbotosho; Onikepe A Folarin; Christian T Happi
Journal:  BMC Infect Dis       Date:  2017-01-31       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.